XENCOR TRIAL RESULTS WEBCAST - XENCOR INC

Financial Performance:

• No specific revenue, profit, or cash flow figures were disclosed, as Zencore is a clinical-stage company in development phases.
• The company highlighted its "robust manufacturing" capabilities, including high-titer cell banks scaling to 2,000 liters and drug substance stability for 60+ months, indicating strong operational efficiency in supply chain readiness.
• No debt or financing details were explicitly quantified in the transcript, though the focus remains on capitalizing the pivotal Phase 3 program launch in 2027.

Guidance and Future Outlook:

• Pivotal Trial Start: The company expects to initiate a registration-enabling Phase 3 study in 2027.
• Regulatory Milestones: An End-of-Phase I meeting with the FDA is planned for the first half of 2027 to discuss an accelerated approval pathway and the confirmatory full approval study.
• Data Cadence: Additional data updates, including Subcutaneous (Sub-Q) dosing results and the full cohort analysis for the 400 mcg/kg IV dose, are expected in the first half of 2027.
• Long-term Goals: Aiming for potential first commercial stage program launch by 2030, with expansion into earlier lines of therapy and combination regimens.

Business Segments and Product Lines:

• XMAP819 (Lead Candidate): A 2+1 format T-cell engager targeting ENPP3 for Clear Cell Renal Cell Carcinoma (ccRCC).
  • Selected Dose: 400 mcg/kg IV target dose identified as the Recommended Phase 3 Dose (RP3D).
  • Efficacy: Phase 1 expansion cohorts showed Objective Response Rates (ORR) of 30% (100 mcg), 44% (200 mcg), and 45.5% (400 mcg) in heavily pre-treated patients.
  • Disease Control: Disease Control Rates (DCR) reached 86.7% at 100 mcg/kg and 81.8% at 400 mcg/kg.
  • Sub-Q Development: Subcutaneous formulation is in dose escalation, with data expected in H1 2027; aims to reduce hospitalization requirements.
• Partnerships: Two ongoing Phase 3 programs with partners:
  • ASP2138 (with Astellas) targeting gastric/GEJ cancer.
  • Zaloridamig (with Amgen) targeting prostate cancer.
• Pipeline Expansion: Opened new cohorts for Papillary RCC, MSS Colorectal Cancer, and Non-Squamous NSCLC, contingent on ENPP3 expression.

Market and Competitive Landscape:

• Target Population: Focus on advanced ccRCC patients who have progressed on prior PD-1/PD-L1 inhibitors and VEGFR TKIs (third-line setting).
• Market Size: Addressable global market for ccRCC estimated at over $11 billion, with ~9,000 eligible patients annually in the US for the post-IO/two-VEGFR TKI setting.
• Competitive Advantage: XMAP819 demonstrates higher ORR compared to current standard-of-care monotherapies (e.g., tivozanib, belzutafen) and combination therapies in heavily pre-treated populations.
• Differentiation: The 2+1 platform offers superior tumor selectivity over 1+1 bispecifics by tuning affinity to spare low-density normal tissues, improving therapeutic windows.

Risks and Challenges:

• Toxicity Management: Initial CRS (Cytokine Release Syndrome), rash, and transaminitis occurred primarily during the priming phase; requires careful management and pre-medication (tocilizumab, dexamethasone).
• Dose Selection Risk: Confirmation of the 400 mcg/kg dose efficacy and safety is pending finalization of the Phase 1 expansion cohort data.
• Regulatory Uncertainty: Accelerated approval requires meeting specific ORR and Duration of Response (DOR) criteria; full approval requires a randomized controlled trial (RCT) comparison.
• Enrollment Complexity: Reliance on heavily pre-treated, poor-risk patients who have exhausted all standard mechanisms (IO, TKI, HIF-2 inhibitors).

Management Commentary and Tone:

• Tone: Highly optimistic and confident, describing the data as a "high watermark" for Phase 1 trials in ccRCC and a potential "breakthrough" therapy.
• Strategic Focus: Emphasis on "excellence in clinical trial execution," robust manufacturing, and the unique 2+1 platform's ability to solve solid tumor targeting issues.
• Commercial Vision: Management views XMAP819 as the company's first potential blockbuster program, with plans to minimize hospitalization and transition to community-based dosing.

Analyst Questions and Answers:

• Accelerated Approval Requirements: Management expects ~100 patients for safety analysis, with efficacy powered on lower bounds of ORR and DOR, potentially achievable with fewer than 100 patients in the specific high-response subgroups.
• Combination Safety: Confidence expressed in combining XMAP819 with PD-1 inhibitors due to lack of cumulative toxicity and non-overlapping AE profiles compared to VEGFR TKIs.
• Dose Selection Rationale: The 400 mcg/kg dose was selected based on consistent safety profiles between 200 and 400 mcg/kg, dose-dependent efficacy trends, and QSP modeling aligning with the top of the sigmoidal curve.
• Subcutaneous Strategy: Sub-Q data will inform whether it becomes the preferred primary formulation or a lifecycle convenience option; expected to be presented in H1 2027.
• Scan Timing: Potential need to adjust scan timing (8-10 weeks vs. 6 weeks) to capture deepening responses that might otherwise be misclassified as progressive disease.
• Other Indications: Early enrolling in papillary RCC, MSS colorectal, and lung cancer; tolerability expected to be similar to ccRCC, though efficacy varies by tumor type.

Other Key Points:

• Patient Case Study: Highlighted a specific patient with metastatic disease who achieved a Complete Response (CR) at 16 months after failing multiple prior lines of therapy, demonstrating durable efficacy.
• Safety Profile: Low rates of treatment discontinuation due to AEs (4.5% dose delays, 0% discontinuations for rash/transaminitis) post-priming phase.
• Operational Efficiency: Progress in reducing inpatient monitoring requirements, aiming to replicate the "no hospitalization" models achieved by partners like Amgen and Astellas.
• Platform Validation: The 2+1 platform's ability to distinguish tumor from normal tissue density is a core differentiator, validated by QSP models and preclinical data showing activity in PD-1 refractory models.